---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-010445"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2022-04-19T23:59:59+00:00"
generated_at: "2026-06-26T06:38:46.683483+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Provectus seeks approval for 1-for-10 to 1-for-50 reverse stock split at June 22 annual meeting

## Summary
- Filed preliminary proxy; meeting scheduled for June 22, 2022; record date April 25, 2022.
- Reverse split ratio range is 1-for-10 to 1-for-50, applies to common stock and Series D/D-1 preferred.
- Authorized share reduction proposal contingent on reverse split approval; both require stockholder approval.
- Stockholders also vote on director election, executive compensation, and auditor ratification.

## SEC filing metadata
- accession: 0001493152-22-010445
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2022-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315222010445/0001493152-22-010445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315222010445/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-010445
- JSON: https://secwatch.observer/filing/0001493152-22-010445.json
- Plain text: https://secwatch.observer/filing/0001493152-22-010445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.